NEW YORK – BostonGene on Thursday said it will collaborate with Takeda to identify molecular drivers and predictive markers in immuno-oncology clinical research.
Takeda will use BostonGene's artificial intelligence-driven multiomics platform to design clinical trials, improve indication selection, and identify biomarker signatures of response and toxicity. BostonGene will analyze Takeda's clinical and laboratory data, including flow cytometry, RNA-seq, and proteomics data.
BostonGene's platform measures molecular and immune markers in the blood via multiparametric flow cytometry and bulk RNA sequencing. In May, the company published a study demonstrating the platform's potential for classifying cancer patients' immune phenotypes and monitoring treatment response in early clinical research.
"Through this collaboration, we look forward to utilizing data and AI to gain more insights into the biology and mechanisms of investigational therapies at the earliest stages," Phuong Khanh Morrow, head of Takeda's Oncology Therapeutic Area Unit, said in a statement. "These data will help us to better understand their potential in certain patient populations and ultimately help advance oncology medicines for patients who need them."
Waltham, Massachusetts-based BostonGene also partnered with the University of Miami's Sylvester Comprehensive Cancer Center last month to validate blood- and bone marrow-based assays for hematologic cancers and recently inked collaborations with other research institutions, including the Parker Institute for Cancer Immunotherapy, Japan's Saga University, Prisma Health, and Duke University School of Medicine.